WCN26-9281 Experience with Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) in the Nephrology Department of Nishi-Kobe Medical Center

Read full text Summarise with VIRAT
Authors: Hiroko Kakita, Tomoki SUETAKE, Kansei Otsuka, Yosuke Nakata, Koichiro Hagihara
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ANCA-associated vasculitis (AAV) is a rare, life-threatening disease that tends to develop in older individuals. Glucocorticoids (GCs) are effective in reducing disease activity; however, GC-related toxicity—such as infections, muscle weakness, and progression of arteriosclerosis—can significantly impair quality of life (QOL). In 2021, avacopan (AVA), a selective C5a receptor antagonist, was approved in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) as a glucocorticoid-sparing therapeutic option.

Fields of Study & Subjects

Vasculitis and related conditions Complement system in diseases Renal Diseases and Glomerulopathies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106331–106331
Publication date
25 March 2026
Language
EN